Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 90, Issue 2, Pages 775-782Publisher
IOS PRESS
DOI: 10.3233/JAD-220611
Keywords
Amyloid-beta; caregiver; dementia; depression; mild cognitive impairment; positron emission tomography
Categories
Funding
- National Institute On Aging of the National Institutes of Health [R01AG053934]
- American College of Radiology Imaging Network
- Alzheimer's Association
- NIH/NIA [K01AG070284]
Ask authors/readers for more resources
This study examines the association between amyloid-beta PET scan results and care-partner wellbeing. The results suggest that elevated amyloid levels are not significantly associated with changes in care-partner wellbeing.
Background: Diagnostic tests, such as amyloid-beta positron emission tomography (PET) scans, can increase appropriate therapeutic management for the underlying causes of cognitive decline. To evaluate the full utility of this diagnostic tool, information is needed on whether results from amyloid-beta PET scans influence care-partner outcomes. Objective: This study examines the extent to which previous disclosure of elevated amyloid (suggestive of Alzheimer's disease (AD) etiology) versus not-elevated amyloid (not suggestive of AD etiology) is associated with changes in care-partner wellbeing. Methods: The study used data derived from a national longitudinal survey of Medicare beneficiaries (n = 921) with mild cognitive impairment (MCI) or dementia and their care-partners. Care-partner wellbeing outcomes included depressive symptoms (PHQ-8), subjective burden (4-item Zarit burden score), and a 3-item measure of loneliness. Change was measured between 4 (Time 1) and 18 (Time 2) months after receiving the scan results. Adjusted linear regression models regressed change (Time 2-Time 1) in each outcome on scan result. Results: Care-partners were primarily white, non-Hispanic, college-educated, and married to the care recipient. Elevated amyloid was not associated with statistically significant Time 1 differences in outcomes or with statistically significant changes in depressive symptoms 0.22 (-0.18, 0.61), subjective burden 0.36 (-0.01, 0.73), or loneliness 0.15 (-0.01, 0.32) for care-partners from one time point to another. Conclusion: Given advances in AD biomarker testing, future research in more diverse samples is needed to understand the influence of scan results on care-partner wellbeing across populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available